Abstract 145P
Background
Biomarkers such as fibroblast growth factor receptor (FGFR) and programmed death-ligand 1 (PD-L1) have been incorporated into the treatment paradigm of metastatic urothelial cancer (mUC). However, there are no data on the FGFR alteration rate and clinical burden of mUC patients in Taiwan. In addition, the association between FGFR status and PD-L1 expression in mUC is rarely studied.
Methods
This is a retrospective, multicenter, non-interventional study to evaluate the association between biomarkers of archived tumor and clinical outcomes including objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in unresectable locally advanced or mUC patients between 2015-2019. FGFR alterations were detected by therascreen FGFR RGQ RT-PCR kit. PD-L1 expression was assessed by the combined positive score (CPS) in DAKO 22C3.
Results
Of the 196 patients, median age was 71, 62% were male, and more than one-third had stage III /IV tumors. FGFR alterations were detected in 13 (6.6%) patients: five patients had FGFR3 translocations and eight had FGFR3 mutations. Among FGFR (+) patients, 15 % (2/13) were PD-L1 CPS≥10, compared with 32 % (58/182) in FGFR (-) ones (Table). A negative association between FGFR status and PD-L1 expression was observed at a CPS cutoff of 5. In general, ORR was 12.2% (95% CI 8.01-17.67) among patients at any 1L treatment. It was 7.7% (95% CI 0.19-36.03) for FGFR (+) patients and 12.6% (95% CI 8.14-18.26) for FGFR (-) ones. Median PFS and OS were 3.58 months (mo.) (95% CI 2.92-4.60) and 7.39 mo. (95% CI 5.95-8.34) for 1L treatment, and 2.3 mo. (95% CI 1.45-3.32) and 5.03 mo. (95% CI 3.55-7.06) for 2L treatment. Survival outcomes were similar irrespective of FGFR status. Table: 145P
FGFR status versus PD-L1 expression in mUC
FGFR (+)(N=13) | FGFR (-)(N=183) | Overall (N=196) | Chi-Square (Nominal p value) | |
PD-L1 level, n (%) | 13 | 182 | 195 | |
PD-L1≥10 | 2 (15) | 58 (32) | 60 (31) | |
PD-L1<10 | 11 (85) | 124 (68) | 135 (69) | 0.3511 |
PD-L1≥5 | 2 (15) | 79 (43) | 81 (42) | |
PD-L1<5 | 11 (85) | 103 (57) | 114 (58) | 0.0476 |
PD-L1≥1 | 5 (38) | 111 (61) | 116 (59) | |
PD-L1<1 | 8 (62) | 71 (39) | 79 (41) | 0.1099 |
Missing | 0 | 1 | 1 |
Conclusions
This retrospective study showed high unmet needs under SoC in mUC in Taiwan, irrespective of FGFR status. The negative association between FGFR status and PD-L1 expression might be considered when deciding personalized treatment based on biomarker profiles.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Johnson & Johnson Taiwan Ltd.
Funding
Johnson & Johnson Taiwan Ltd.
Disclosure
Y. Feng: Financial Interests, Personal, Other, Consultant: Roche, Novartis, AbbVie. H. Huang: Financial Interests, Personal, Invited Speaker, Employee: Janssen Taiwan. All other authors have declared no conflicts of interest.
Resources from the same session
197P - The risk of uterine cervical cancer in inflammatory bowel disease: An updated systematic review and meta-analysis
Presenter: Hee Man Kim
Session: Poster viewing 03
198P - Geographic and demographic access to brachytherapy in India, with a special emphasis on gynaecological cancers
Presenter: Abhishek Krishna
Session: Poster viewing 03
199P - Prevalence of cervical cancer in Uzbekistan: A population based study
Presenter: Sayde Djanklich
Session: Poster viewing 03
200P - A retrospective institutional analysis on gynecological malignant mixed Mullerian tumors
Presenter: Monik Patel
Session: Poster viewing 03
201P - Immunotherapy in advanced mismatch repair deficiency endometrial cancer: A real-world single center experience
Presenter: Amit Rauthan
Session: Poster viewing 03
203TiP - Autophagy as a target for therapy in ovarian cancer: A phase II randomized trial with biomarker correlation (ATOC Trial)
Presenter: Luxitaa Goenka
Session: Poster viewing 03
210P - Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
Presenter: Lei Chen
Session: Poster viewing 03
211P - Chemotherapy delivery time affects anti-lymphoma treatment outcome in a sex-dependent manner
Presenter: Yeonsoo Park
Session: Poster viewing 03